Ainos (NASDAQ:AIMD) Director Ting-Chuan Lee Sells 109,988 Shares of Stock

Ainos, Inc. (NASDAQ:AIMD) Director Ting-Chuan Lee sold 109,988 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $1.90, for a total transaction of $208,977.20. Following the completion of the sale, the director owned 807,417 shares in the company, valued at $1,534,092.30. This represents a 11.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ainos Trading Down 19.0%

AIMD opened at $2.56 on Thursday. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.55 and a quick ratio of 0.50. Ainos, Inc. has a fifty-two week low of $1.26 and a fifty-two week high of $4.50. The firm has a market capitalization of $21.81 million, a PE ratio of -0.89 and a beta of 2.29. The company’s 50-day moving average is $1.67 and its 200 day moving average is $1.83.

Ainos (NASDAQ:AIMD) last posted its earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter. Ainos had a negative return on equity of 160.55% and a negative net margin of 11,912.10%.

Institutional Investors Weigh In On Ainos

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mariner LLC purchased a new stake in Ainos in the 4th quarter valued at about $37,000. Two Sigma Investments LP bought a new position in shares of Ainos during the 3rd quarter valued at approximately $80,000. DRW Securities LLC grew its position in shares of Ainos by 272.6% during the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after acquiring an additional 48,439 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Ainos by 13.1% during the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after acquiring an additional 7,700 shares during the period.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ainos presently has an average rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical?stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI?401, is an inhaled formulation of ibuprofen in a dry powder format.